FDA Warning Letter: Major CGMP, Quality System and OTC Drug Violations
FDA Warning Letter: Major CGMP, Quality System and OTC Drug Violations This FDA warning letter identifies significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals under 21 CFR Parts 210 and 211. FDA concluded that the firm’s manufacturing, processing, packing, and holding controls did not conform to CGMP requirements, resulting in drug … Read more